Summit Therapeutics Files 8-K for Regulation FD Disclosure on Feb 15, 2024
Ticker: SMMT · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Regulatory Filing, Disclosure
TL;DR
**Summit Therapeutics filed an 8-K on Feb 15, 2024, for Regulation FD disclosure, but specific details are not yet available.**
AI Summary
Summit Therapeutics Inc. filed an 8-K with the SEC on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates disclosures under Regulation FD and the inclusion of Financial Statements and Exhibits. Specific details regarding the nature of the disclosure or any associated dollar amounts are not provided in the available text.
Why It Matters
This filing indicates that Summit Therapeutics Inc. has disclosed material non-public information, or is filing required financial documents, which could impact investors once the full details are made public.
Risk Assessment
Risk Level: medium — The filing itself is a standard regulatory report, and without the content of the Regulation FD disclosure, no specific risks can be identified.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- United States Securities and Exchange Commission (company) — Regulator
- February 14, 2024 (date) — Date of Earliest Event Reported
- February 15, 2024 (date) — Filed As Of Date
- Delaware (location) — State of Incorporation for Registrant
- Miami, FL (location) — Principal Executive Offices
FAQ
What is the exact name of the registrant?
The exact name of the registrant is Summit Therapeutics Inc.
What was the date of the earliest event reported in this 8-K?
The date of the earliest event reported was February 14, 2024.
What is the state of incorporation for Summit Therapeutics Inc.?
Summit Therapeutics Inc. is incorporated in Delaware.
What specific items are reported in this 8-K filing?
This 8-K filing reports on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the registrant's principal executive offices address?
The registrant's principal executive offices address is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-15 17:25:38
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240214.htm (8-K) — 29KB
- a20240201opcohcconfinves.htm (EX-99.1) — 30KB
- a20240201opcohcconfinves001.jpg (GRAPHIC) — 93KB
- a20240201opcohcconfinves002.jpg (GRAPHIC) — 250KB
- a20240201opcohcconfinves003.jpg (GRAPHIC) — 111KB
- a20240201opcohcconfinves004.jpg (GRAPHIC) — 114KB
- a20240201opcohcconfinves005.jpg (GRAPHIC) — 102KB
- a20240201opcohcconfinves006.jpg (GRAPHIC) — 75KB
- a20240201opcohcconfinves007.jpg (GRAPHIC) — 103KB
- a20240201opcohcconfinves008.jpg (GRAPHIC) — 120KB
- a20240201opcohcconfinves009.jpg (GRAPHIC) — 159KB
- a20240201opcohcconfinves010.jpg (GRAPHIC) — 119KB
- a20240201opcohcconfinves011.jpg (GRAPHIC) — 136KB
- a20240201opcohcconfinves012.jpg (GRAPHIC) — 118KB
- a20240201opcohcconfinves013.jpg (GRAPHIC) — 129KB
- a20240201opcohcconfinves014.jpg (GRAPHIC) — 109KB
- a20240201opcohcconfinves015.jpg (GRAPHIC) — 134KB
- a20240201opcohcconfinves016.jpg (GRAPHIC) — 211KB
- a20240201opcohcconfinves017.jpg (GRAPHIC) — 104KB
- a20240201opcohcconfinves018.jpg (GRAPHIC) — 95KB
- a20240201opcohcconfinves019.jpg (GRAPHIC) — 92KB
- a20240201opcohcconfinves020.jpg (GRAPHIC) — 89KB
- a20240201opcohcconfinves021.jpg (GRAPHIC) — 32KB
- a20240201opcohcconfinves022.jpg (GRAPHIC) — 80KB
- 0001599298-24-000025.txt ( ) — 3770KB
- smmt-20240214.xsd (EX-101.SCH) — 2KB
- smmt-20240214_def.xml (EX-101.DEF) — 14KB
- smmt-20240214_lab.xml (EX-101.LAB) — 28KB
- smmt-20240214_pre.xml (EX-101.PRE) — 15KB
- smmt-20240214_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 14, 2024, Summit Therapeutics, Inc. (the "Company") presented at Oppenheimer's 34th Annual Healthcare Life Sciences Conference, which was held virtually. A copy of the presentation is attached as Exhibit 99.1 to this current Report on Form 8-K and is incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation Slides made available on February 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: February 15, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)